There are just two companies, Abbott and Dexcom, that dominate the $12 billion continuous glucose monitoring (CGM) market. Both rely on the same basic approach: a filament-based sensor, inserted 5-10mm into the skin using a hypodermic needle. It works, but it's invasive, expensive, and limited to measuring a